News
Polyphor to merge with EnBiotix
EnBiotix has purchased murepavadin, an investigational inhaled antibiotic to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), from Polyphor.
The two companies also entered into an agreement to merge, wherein Polyphor will acquire all EnBiotix stock in exchange for Polyphor stock newly issued upon closing. The merger is expected to close by year’s end, assuming the agreement is approved by both companies’ shareholders, as well as assessment of tax consequences and other conditions.
Type: industry
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins